TG Therapeutics challenges Roche with FDA filing for CLL drug
pharmaphorum
DECEMBER 2, 2020
Aside from Gazyvaro, CLL can be treated with older chemotherapy agents, or Roche/AbbVie’s Venclexta (venetoclax) in some instances, and the fast track tag showed the FDA considered the combination to be a promising new contender on the market. TG said it expects the data submission to be complete in the first half of 2021.
52 
Let's personalize your content